Stubblefield PG, Borgatta L. Complications of induced abortion. In: Pearlman MD, Tintinalli JE, Dyne PL, eds. Obstetric and gynecological emergencies: diagnosis and management. New York: McGraw Hill, 2004:65–86.
329.
Paul M, Lichtenberg ES, Borgatta L, et al. Management of unintended and abnormal pregnancy. Comprehensive abortion care. Oxford: Wiley-Blackwell, 2009.
330.
Spitz IM, Bardin CW, Benton L, et al. Early pregnancy terminations with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241–1247.
331.
Goldberg AB, Greenberg BS, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001;344:38–47.
332.
Schaff EA, Fielding LS, Eisinger SH, et al. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 2000;61:41–46.
333.
Schaff EA, Fielding SL, Westoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA 2000;84:1948–1953.
334.
Schaff EA, Stadalius LS, Eisinger SH, et al. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. JFam Pract 1997;44:353–360.
335.
Schaff EA, DiDenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception 2005;71:22-5 336.
Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997;90:735–738.
337.
Fjerstad NP, Trussell J, Sivin I et al. Rates of serious infection after changes in regimens for medical abortion. N Engl J Med 2009;361:145–151.
338.
Mifeprex Medication Guide. New York: Danco Laboratories, LLC.
339.
Ashok PW, Flett GM, Templeton A. Termination of pregnancy at 9–13 weeks’ amenorrhea with mifepristone and misoprostol [Letter]. Lancet 1998;352:542–543.
340.
Creinin MD, Vittinghoff E, Keder L, et al. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception 1996;53:321–327.
341.
Borgatta, Mullaly B, Vragovic O, et al. Misoprostol as the primary agent for medical abortion in a low income urban setting. Contraception 2004;70:121–126.
342.
Allen RH, Westhoff C, De Nonno L, et al. Curettage after mifepristone induced abortion: frequency, timing and indications. Obstet Gynecol 2001;98:101–106.
343.